

MITHRA PHARMACEUTICALS SA/NV ANNOUNCES THE LAST PATIENT ENROLLMENT IN THE PHARMACODYNAMICS & PHARMACOKINETICS STUDIES OF THE ZORELINE® IMPLANT 10.8 MG

- The 142 patients needed have now been enrolled
 - The enrolment is 6 weeks ahead of schedule
- Only 3 patients (2%) dropped out the study (28 were expected)

Liège, Belgium 18 November 2015 – Regulated information: Mithra Pharmaceuticals, leader in Women’s Health and cutting-edge technological company in the field of API slow-release drugs based on polymere (subcutaneous implants, biocompatible rings, hormonal IUD’s), announced today that it has enrolled the last patient required in the pharmacodynamics & pharmacokinetics studies of its Zoreline® subcutaneous implant 10.8 mg.

Among the 163 screened patients, 142 patients were enrolled in 10 months and two weeks, On these 142 patients, 40 finished the treatment, 99 are still under treatment and 3 patients dropped out the study: one for medical reasons and two personal reasons, namely a 2% drop-out rate instead compared to the 20% expected rate.

Zoreline® is a biodegradable subcutaneous under development, which should find applications for the treatment of breast cancer, benign gynaecological conditions such as endometriosis or uterine fibroid as well as prostate cancer. Zoreline® is currently developed by Novalon, a 50% subsidiary of Mithra. Novalon is developing a one month implant that contains 3.6 mg of Goserelin and a three months implant that contains 10.8 mg of Goserelin, a synthetic analogue of a naturally hormone, luteinizing hormone releasing hormone (LHRH) that regulates many endocrinological processes in the body.

“We are very pleased that we have reached the enrolment goals of these studies ahead of schedule”, explains Valérie Gordenne, Chief Scientific Officer of Mithra Pharmaceuticals. “This represents a great achievement for the entire team working on this project. We are now looking forward for the in-interim results of December.”

For more information, please contact:

Press

Julie Dessart

Chief Communication Officer

+32 4 349 28 22

+32 475 86 41 75

press@mithra.com

Investor Relations

François Fornieri, CEO/ Steven Peters, CFO/ Julie Dessart, CCO/ Jean-Manuel Fontaine, PRO

+32 4 349 28 22

investorrelations@mithra.com

To subscribe to Mithra's newsletter, visit investors.mithra.com

About Mithra

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. dr. Jean-Michel Foidart, is a pharmaceutical company focused on Women's Health. Mithra's mission is to support and assist women at every stage of their life, thereby improving their overall quality of life. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and generic products in four therapeutic fields of women's health, fertility and contraception, menopause and osteoporosis, vaginal infections and cancers.

Mithra has a total headcount of approximately 85 staff members and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.